Article
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
The Lancet. Oncology - 1 Mar 2012
Rosell Rafael, Carcereny Enric, Gervais Radj, Vergnenegre Alain, Massuti Bartomeu, Felip Enriqueta, Palmero Ramon, Garcia-Gomez Ramon, Pallares Cinta, Sanchez Jose Miguel, Porta Rut, Cobo Manuel, Garrido Pilar, Longo Flavia, Moran Teresa, Insa Amelia, De Marinis Filippo, Corre Romain, Bover Isabel, Illiano Alfonso, Dansin Eric, de Castro Javier, Milella Michele, Reguart Noemi, Altavilla Giuseppe, Jimenez Ulpiano, Provencio Mariano, Moreno Miguel Angel, Terrasa Josefa, Muñoz-Langa Jose, Valdivia Javier, Isla Dolores, Domine Manuel, Molinier Olivier, Mazieres Julien, Baize Nathalie, Garcia-Campelo Rosario, Robinet Gilles, Rodriguez-Abreu Delvys, Lopez-Vivanco Guillermo, Gebbia Vittorio, Ferrera-Delgado Lioba, Bombaron Pierre, Bernabe Reyes, Bearz Alessandra, Artal Angel, Cortesi Enrico, Rolfo Christian, Sanchez-Ronco Maria, Drozdowskyj Ana, Queralt Cristina, de Aguirre Itziar, Ramirez Jose Luis, Sanchez Jose Javier, Molina Miguel Angel, Taron Miquel, Paz-Ares Luis
Abstract excerpt
BACKGROUND: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations. We aimed to assess the safety and efficacy of erlotinib compared with standard chemotherapy for first-line treatment of European patients with advanced EGFR-mutation positive NSCLC....
Read the complete abstract on PubMed